Share This Article:

Aspirin resistance in young men with Type 2 diabetes

Full-Text HTML Download Download as PDF (Size:121KB) PP. 72-76
DOI: 10.4236/jdm.2014.41013    3,463 Downloads   5,319 Views Citations


Objective: Aspirin resistance (AR) or poor response to aspirin is said to be high among subjects with diabetes and more so in patients with poor glycemic control. The aim of our study was to evaluate the prevalence of AR among subjects with diabetes with moderate glycemic control and its association with inflammatory markers and cytokines. Design: This is a single-center open-label prospective clinical study. Methods: The study included 142 young male veterans (mean age of 49years) with Type 2 diabetes, with HbA1C of 7.7 ± 1.1. Urinary 11-dehydro-thromboxane beta-2 (11DhTx2) concentrations measured by immunoassay are the primary outcome measures. Results: Urinary 11DhTxB2 levels ≥ 1500 pg/mg of creatinine is considered as AR. Approximately 53% of subjects had AR. There are no significant differences in the clinical parameters, such as age, history of hypertension or BMI, waist to hip ratio; as well as biochemical parameters, such as HbA1C, lipid parameters or serum creatinine, between subjects with or without AR. Levels of 11DhTxB2 /cre correlated with history of CAD, abdominal fat content and IL-6 levels (p < 0.01) as well as abdominal fat content and IL-6 levels; duration of diabetes and history of CAD. Conclusions: Aspirin resistance is common in subjects with diabetes even with moderate control. Additional measures to improve aspirin response should be considered. Further studies with larger groups are needed to clarify the AR with various associated risk factors.

Cite this paper

Yaturu, S. , Dier, E. , Cui, H. and Mousa, S. (2014) Aspirin resistance in young men with Type 2 diabetes. Journal of Diabetes Mellitus, 4, 72-76. doi: 10.4236/jdm.2014.41013.

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.